Servier signs leukaemia deal
February 19, 2014Research and Development, Sales and Marketing Servier, UCART19, car, cellectis, leaukaemia
French firms Servier and small biopharma cancer specialist Cellectis have signed a deal to develop and commercialise one drug targeting …
Boehringer in hot water over Pradaxa risks
February 19, 2014Sales and Marketing Boehringer, Pradaxa, Xarelto, dabigatran, lawsuit
Boehringer Ingelheim attempted to delay and revise the publication of important drug information surrounding its new anticoagulant Pradaxa. This is …
Vimizin shown green light
February 19, 2014Research and Development, Sales and Marketing BioMarin, FDA, congenital enzyme disorder, vimizin
Regulators have shown the green light to BioMarin Pharmaceutical’s Vimizim as a treatment for a rare enzyme deficiency which affects …
NHS England delays patient data roll-out
February 19, 2014Medical Communications, Sales and Marketing England, HSCIC, NHS, care data, care.data, data, patients
The giant NHS database that could allow pharma firms to buy into patient records will now not be launched until …
EMA hires Accenture IT head
February 19, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dina Tsiambaou, EMA, IT
The European Medicines Agency (EMA) has welcomed Dina Tsiambaou as the new head of its Information Technology department. Tsiambaou joins …
Forest sold to Actavis for $25 billion
February 18, 2014Sales and Marketing Actavis, CNS, Forest, acquisition, labs, merger, synergy
The rumours of a substantial deal for Forest have been proven true after Actavis announced this afternoon that it will …
Bayer ‘disappointed’ with FDA
February 18, 2014Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban
Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …
FDA seeks more specialisation in agency structure
February 18, 2014Manufacturing and Production FDA, GMP, ORA, fdasia, hamburg, opq, ufi
An internal review of the US Food and Drug Administration has concluded that the agency needs to restructure its compliance …
GSK starts rare blood trial
February 18, 2014Research and Development, Sales and Marketing GSK, blood, mepolizumab
GlaxoSmithKline has begun a Phase III study to look at mepolizumab in a rare condition characterised by vasculitis – widespread …
German law could see pharma discounts published
February 18, 2014Sales and Marketing AMNOG, Germany, IMS, NICE, prices
Pharma companies are apprehensive about German lawmakers opening Pandora’s Box this week if they go ahead with plans to publish …
Drug sellers charged for smuggling cancer drugs into US
February 18, 2014Manufacturing and Production, Sales and Marketing Cancer, FDA, US, smuggling
Two individuals in the US have been prosecuted for smuggling adulterated and misbranded prescription cancer treatments from Turkey and other …
Genes in Space – you don’t need a lab coat to cure cancer
February 18, 2014Medical Communications, Sales and Marketing CRUK, Cancer, app, digital, games, genes in space
As the UK’s leading cancer research charity launches a new gaming app for smartphones, Pharmafile talks to CRUK about just …
EFPIA appoints comms head from Lilly
February 18, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EFPIA, English, liam, lilly
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has hired its new comms director from Eli Lilly. Liam English …
Jazz Pharma chooses Ireland for first facility
February 17, 2014Manufacturing and Production API, Ireland, azur, jazz pharma
Jazz Pharmaceuticals will build its first in-house manufacturing facility in Ireland after years of relying on outsourcing to meet its …
Pharma manufacturing news in brief
February 17, 2014Manufacturing and Production Advaxis, Alexion, Berkshire Sterile Manufacturing, Catalent, Hospira, Shire
Hospira has made significant progress in restoring quality compliance at its facilities in Rocky Mount and Austin, which were the …
Novartis pays out for US biotech
February 17, 2014Research and Development, Sales and Marketing Cancer, Novartis, Vaccine, costim pharmaceuticals
Novartis is looking to shore up its cancer immunotherapy pipeline with the purchase of oncology specialist CoStim Pharmaceuticals. The Cambridge, …
Aveo and Astellas part ways
February 17, 2014Sales and Marketing Astellas, Aveo, Boehringer, EMA, tivozanib
Aveo Oncology and Astellas Pharma are to abandon their three-year old collaboration and licence agreement for investigational tyrosine kinase inhibitor …
NICE: new system will allow more drugs on NHS
February 17, 2014Sales and Marketing DH, Dillon, DoH, NHS, NICE, QALY
NICE has said that it will be able to approve more medicines under a new drug pricing policy, but warns …
Germany focus: strength with control
February 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMNOG, EFPIA, Germany, IQWIG, NHS, NICE
Germany is the biggest pharmaceutical market in Europe and one of the biggest in the world, but new systems and …
Shire chief financial officer steps down
February 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, hetherington
Shire’s chief financial officer (CFO) Graham Hetherington has notified the company of his decision to step down. Flemming Ornskov, Shire …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
